Table 1.
Patient characteristics
| Baseline characteristics Parameters | Cohort 1 (N=235) N, (%) | Cohort 2 (N=407) N, (%) |
|---|---|---|
| Age, yrs, mean±SD | 49.3±7.1 | 46.6±9.4 |
| Female, n (%) | 45 (19.1) | 107 (26.3) |
| VL (HIV-RNA) <50 copies/mL, n (%)a at study enrolment | 192 (85) | 298 (74.9) |
| CD4+<100 cells/µL, n (%)b at study enrolment | 7 (3.1) | 25 (6.2) |
| Duration of HIV infection, n (%) | ||
| 0–1 year | 0 | 53 (13.0) |
| >1–10 years | 6 (2.6) | 82 (20.1) |
| >10–15 years | 62 (26.4) | 66 (16.2) |
| >15–20 years | 89 (37.9) | 85 (20.9) |
| >20 years | 76 (32.3) | 110 (27.0) |
| NA | 2 (0.9) | 11 (2.7) |
| CDC clinical stage, n (%) | ||
| A | 30 (12.8) | 139 (34.2) |
| B | 80 (34.0) | 121 (29.7) |
| C | 125 (53.2) | 147 (36.1) |
| Time since first DRV dose (days), at study enrolment – mean±SD | 1242±208 | 501±402 |
| Study Duration, days – mean±SD | 812±286 | 583±188 |
| DRV dose at study entry, mg/day, n (%) | ||
| 1200 | 232 | 262 |
| 800 | 3 | 145 |
a
VL data only available in 226 Cohort 1 and 398 Cohort 2 patients.
b
CD4+ data only available in 226 Cohort 1 and 403 Cohort 2 patients.